Summary:
- The article examines the current clinical and preclinical research regarding the use of cannabinoids (CBD and THC) as potential therapeutic agents in oncology.
- It distinguishes between the palliative benefits of cannabis—such as managing chemotherapy-induced nausea, pain, and appetite loss—and the ongoing, largely inconclusive research into the direct anti-tumor effects of cannabinoids in human subjects.
- The text emphasizes the importance of evidence-based medicine, cautioning patients against relying solely on anecdotal evidence and highlighting the need for further rigorous, large-scale clinical trials to establish safety and efficacy.